6 results about "Neomycin sulphate" patented technology

The invention provides a wound dressing for diminishing inflammation, easing pain and promoting wound healing and a preparation method thereof. The wound dressing capable of diminishing inflammation, easing pain and promoting wound healing is prepared from the following components in parts by mass: 6 to 10 parts of oxidized sodium alginate, 7 to 9 parts of hydrazide gelatin, 1 to 1.5 parts of tannic acid, 8 to 12 parts of polyethylene glycol, 0.05 to 0.1 part of cannabidiol, 0.05 to 0.1 part of neomycin sulfate, 0.2 to 0.3 part of 2-roots alcohol, 0.02 to 0.04 part of vitamin C palmitate and 0.03 to 0.1 part of epsilon-polylysine. The dressing can achieve excellent effects of diminishing inflammation, easing pain and promoting wound healing through synergistic cooperation of all the components.

The invention relates to the field of medicinal emulsifiable paste, in particular to compound fluconazole emulsifiable paste and a preparation method thereof. The compound fluconazole emulsifiable paste is prepared from the following components in parts by weight: 0.6 to 5 parts of fluconazole, 0.2 to 2 parts of neomycin sulfate, 0.1 to 0.2 part of triamcinolone acetonide, 5 to 15 parts of stearic acid, 10 to 25 parts of white vaseline, 2 to 8 parts of glyceryl monostearate, 0.5 to 3 parts of medicinal dimeticone, 1 to 5 parts of polysorbate-80, 0.1 to 0.3 part of sorbic acid, 0.1 to 1 part of vitamin E, 0.01 to 0.1 part of EDTA (Ethylene Diamine Tetraacetic Acid) disodium, 5 to 15 parts of glycerol and the balance of purified water, wherein the total amount is 100 parts. According to the application, the antioxidant property of the cream is improved by adding the vitamin E and the EDTA disodium, the vitamin E is used for directly scavenging free radicals, the EDTA disodium is used for eliminating an oxidation catalyst, and the quality guarantee period of the cream can be remarkably prolonged and the drug effect can be maintained by combining the vitamin E and the EDTA disodium.

The application relates to the field of aquaculture, and particularly discloses a method for cultivating oyster larvae, which comprises the following steps: S1, fertilized eggs are developed into D-shaped larvae in seawater at 22 DEG C for 20-24 hours; S2, the D-shaped larvae are cultivated under the condition that the temperature is 22-24 DEG C and the salinity is 29-31 ‰, feed and growth nutrient solution are fed daily, water is changed daily, after the D-shaped larvae appear eye spots, a larval collector is put in, and algal feed and growth promoting solution are fed daily, the larvae are cultivated into 0.8-1 mm juvenile shellfish, and are transferred to sea cultivation; the growth nutrient solution comprises the following components in weight parts: 1-2 parts of a small molecule peptide solution, 0.01-0.03 parts of neomycin sulfate powder, 0.5-1 part of corn starch, 2-4 parts of modified montmorillonite, and 10-15 parts of water. The method for cultivating oyster larvae has the advantages that the survival rate of the larvae is improved, the growth speed is accelerated, and the metamorphosis and attachment rate is improved.

The application belongs to the technical field of biological medicine, and particularly relates to a drug for treating scald infection and a preparation method and application thereof. The application prepares a drug for treating scald infection, which is self-assembled from a tetrahedral framework nucleic acid and an antibiotic. The application preferably selects a tFNAs-NeoS drug, the drug has a simple preparation method, a high loading efficiency of neomycin sulfate, good stability in a complex biological medium, reduced cytotoxicity and effective dose of the antibiotic NeoS, better biological safety than tFNAs, and slowed generation of bacterial drug resistance. In terms of treating scald wound infection, the tFNAs-NeoS has better effects of promoting wound healing and biological safety than NeoS. Therefore, the prepared tFNAs-NeoS overcomes the problem of overuse of antibiotics, and has a good clinical application prospect.

The invention relates to the field of veterinary drugs, in particular to a pharmaceutical composition for preventing and treating rabbit dermatomycosis as well as a preparation method and application thereof. The pharmaceutical composition is prepared from the following raw materials in percentage by weight: 0.5%-2% of clotrimazole, 1%-5% of 5% gentamicin sulfate powder, 20%-40% of sulfur powder, 50%-75% of talcum powder, 2%-6% of 32.5% neomycin sulfate powder and the balance of water. According to the composition, clotrimazole is introduced as a core antifungal component, a targeting action mechanism of specific inhibition of fungal cytochrome P-450 of clotrimazole is utilized, and a non-specific bactericidal effect of sulfur powder is combined, so that synergistic interaction is realized.

The present application belongs to the technical field of aquaculture, and discloses a compound synergist of neomycin sulfate as well as a preparation method and application thereof. The present application discloses, for the first time, the application of Wedelia prostrata extract, Gastrodia extract and Picrasma extract in inhibiting the growth of Vibrio in vitro and in preventing and treating the glass fry disease of South American white shrimp caused by Vibrio infection. Experimental verification shows that the Wedelia prostrata extract, Gastrodia extract and Picrasma extract have good effects in inhibiting the growth of Vibrio in vitro when used alone, in combination with each other or simultaneously. Meanwhile, in view of the treatment of Vibrio infection causing the glass fry disease, the above extracts are used in combination with neomycin sulfate, so as to overcome the objective problem of low or weak efficacy of neomycin sulfate at a recommended dose, and to simultaneously achieve the enhancement of the efficacy of neomycin sulfate after being used in combination with neomycin sulfate, and the reduction of the usage amount of neomycin sulfate.